OMEICOS
OMEICOS Therapeutics develops small molecule therapies targeting natural cell-protective pathways to treat cardiovascular, inflammatory, and mitochondrial diseases. Its lead compound, OMT-28, is currently in clinical development for atrial fibrillation, coronary artery disease, and primary mitochondriopathies. The company's proprietary approach utilizes omega-3 fatty acid metabolism to address inflammation and mitochondrial dysfunction.
Healthtech
Biotechnology
Pharmaceuticals
Funding summary
- Total raised
- €17.0M
- Funding rounds
- 1
Investors in OMEICOS
Investors on record for OMEICOS. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like OMEICOS?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors